title: [Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases].
abstract: We created a registry to evaluate long term outcome, efficacy and adverse events for children treated wit TNF-alpha inhibitors in Switzerland. 106 patients (68 female/38 male) were included. 61 patients were treated with Etanercept (Enbrel) and 45 with Infliximab (Remicade). Concomitant treatment at baseline included corticosteroids in 26% and Methotrexate in 75% of the patients. Subjective disease activity three months after initiation of TNF-alpha was better in 81%, worse in 4% and stable in 15% of the patients. In total 24 adverse events in 21 patients were reported. Treatment with TNF-alpha inhibitors seems to be safe and effective for children and adolescents with rheumatologic diseases.
authors.affiliation: Unikinderklinik für Kinderheilkunde+Uniklinik für Rheumatologie, Klinische Immunologie+Allergologie, Inselspital, Universitätsspital Bern.
authors.forename: M J
authors.initials: MJ
authors.lastname: Sauvain
authors.forename: S B
authors.initials: SB
authors.lastname: Schalm
authors.forename: G
authors.initials: G
authors.lastname: Bérthet
authors.forename: D
authors.initials: D
authors.lastname: Bolz
authors.forename: E
authors.initials: E
authors.lastname: Cannizzaro
authors.forename: M
authors.initials: M
authors.lastname: Hofer
authors.forename: D
authors.initials: D
authors.lastname: Kaiser
authors.forename: R K
authors.initials: RK
authors.lastname: Saurenmann
authors.forename: I B
authors.initials: IB
authors.lastname: Bolt
mesh_terms: D000293:Adolescent; D016907:Adverse Drug Reaction Reporting Systems; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy; D002648:Child; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D000069285:Infliximab; D011358:Product Surveillance, Postmarketing; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012042:Registries; D012216:Rheumatic Diseases / Q000188:drug therapy*; D013557:Switzerland; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014605:Uveitis / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept